157 related articles for article (PubMed ID: 22361037)
1. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations.
Gurzu S; Jung I
Pathol Res Pract; 2012 Mar; 208(3):163-6. PubMed ID: 22361037
[TBL] [Abstract][Full Text] [Related]
2. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
Landau MS; Kuan SF; Chiosea S; Pai RK
Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
[TBL] [Abstract][Full Text] [Related]
3. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas.
Bayrak R; Yenidünya S; Haltas H
Pathol Res Pract; 2011 Mar; 207(3):156-60. PubMed ID: 21282015
[TBL] [Abstract][Full Text] [Related]
4. Serrated pathway adenocarcinomas: molecular and immunohistochemical insights into their recognition.
Gurzu S; Szentirmay Z; Toth E; Bara T; Bara T; Jung I
PLoS One; 2013; 8(3):e57699. PubMed ID: 23469219
[TBL] [Abstract][Full Text] [Related]
5. Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
McCluggage WG; Shah R; Connolly LE; McBride HA
Int J Gynecol Pathol; 2008 Jan; 27(1):92-100. PubMed ID: 18156982
[TBL] [Abstract][Full Text] [Related]
6. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.
Bayrak R; Haltas H; Yenidunya S
Diagn Pathol; 2012 Jan; 7():9. PubMed ID: 22268990
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary.
Park SY; Kim HS; Hong EK; Kim WH
Hum Pathol; 2002 Nov; 33(11):1078-85. PubMed ID: 12454811
[TBL] [Abstract][Full Text] [Related]
8. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
Su YC; Hsu YC; Chai CY
Kaohsiung J Med Sci; 2006 Jan; 22(1):14-9. PubMed ID: 16570563
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability.
McGregor DK; Wu TT; Rashid A; Luthra R; Hamilton SR
Am J Surg Pathol; 2004 Jun; 28(6):712-8. PubMed ID: 15166663
[TBL] [Abstract][Full Text] [Related]
11. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung].
Zou SM; Lin DM; Lü N; Liu XY; Wen P; Liu FS
Zhonghua Yi Xue Za Zhi; 2003 Aug; 83(15):1350-2. PubMed ID: 12930693
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors.
Tot T
Cancer; 1999 Jan; 85(1):171-7. PubMed ID: 9921990
[TBL] [Abstract][Full Text] [Related]
13. Tubular carcinoids of the appendix: the CK7/CK20 immunophenotype can be a diagnostic pitfall.
Matsukuma KE; Montgomery EA
J Clin Pathol; 2012 Jul; 65(7):666-8. PubMed ID: 22461652
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 7 and 20 expression in choroid plexus tumors: utility in differentiating these neoplasms from metastatic carcinomas.
Gyure KA; Morrison AL
Mod Pathol; 2000 Jun; 13(6):638-43. PubMed ID: 10874668
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.
Cai YC; Banner B; Glickman J; Odze RD
Hum Pathol; 2001 Oct; 32(10):1087-93. PubMed ID: 11679943
[TBL] [Abstract][Full Text] [Related]
16. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma.
Yamagishi H; Imai Y; Okamura T; Fukuda K; Ono Y; Ban S; Inoue T; Ueda Y
J Gastroenterol Hepatol; 2013 Dec; 28(12):1815-22. PubMed ID: 23808938
[TBL] [Abstract][Full Text] [Related]
17. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype.
Tot T
Med Sci Monit; 2004 May; 10(5):BR139-43. PubMed ID: 15114262
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
[TBL] [Abstract][Full Text] [Related]
19. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and immunohistochemical study of 20 choroid plexus tumors: their histological diversity and the expression of markers useful for differentiation from metastatic cancer.
Ikota H; Tanaka Y; Yokoo H; Nakazato Y
Brain Tumor Pathol; 2011 Jul; 28(3):215-21. PubMed ID: 21394517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
